Home > Newsletters > Drug Industry Daily > Idenix Confident in Safety Advantage of Hep C Drug Despite Trial Hold
Drug Industry Daily
Aug. 17, 2012 | Vol. 11 No. 162
Idenix Confident in Safety Advantage of Hep C Drug Despite Trial Hold
Idenix remains confident that its lead product candidate, hepatitis C drug IDX184, has a safety advantage over a similar Bristol-Myers Squibb (BMS) competitor despite a partial clinical hold placed on IDX184 following adverse heart events seen in BMS’ trials.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.